CN112402425A - Application of 3, 5-dinitrophenyl-pyrazolo [3,4-d ] [1,3] oxazine as tumor drug resistance reversal agent - Google Patents
Application of 3, 5-dinitrophenyl-pyrazolo [3,4-d ] [1,3] oxazine as tumor drug resistance reversal agent Download PDFInfo
- Publication number
- CN112402425A CN112402425A CN202011350126.3A CN202011350126A CN112402425A CN 112402425 A CN112402425 A CN 112402425A CN 202011350126 A CN202011350126 A CN 202011350126A CN 112402425 A CN112402425 A CN 112402425A
- Authority
- CN
- China
- Prior art keywords
- dinitrophenyl
- pyrazolo
- drug
- tumor
- oxazine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 36
- 206010059866 Drug resistance Diseases 0.000 title claims abstract description 24
- VNBZKARPPZQORA-UHFFFAOYSA-N 3-(3,5-dinitrophenyl)pyrazolo[3,4-d][1,3]oxazine Chemical compound [N+](=O)([O-])C=1C=C(C=C(C=1)[N+](=O)[O-])C1=NN=C2N=COC=C21 VNBZKARPPZQORA-UHFFFAOYSA-N 0.000 title claims abstract description 12
- 239000012313 reversal agent Substances 0.000 title claims abstract description 12
- 239000003814 drug Substances 0.000 claims abstract description 45
- 229940079593 drug Drugs 0.000 claims abstract description 40
- 150000001875 compounds Chemical class 0.000 claims abstract description 22
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 102000013013 Member 2 Subfamily G ATP Binding Cassette Transporter Human genes 0.000 claims description 15
- 108010090306 Member 2 Subfamily G ATP Binding Cassette Transporter Proteins 0.000 claims description 15
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 10
- 229960001156 mitoxantrone Drugs 0.000 claims description 9
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims description 9
- 239000003112 inhibitor Substances 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 5
- XIBUCANHNLRVFI-UHFFFAOYSA-N 6-(3,5-dinitrophenyl)-1-phenylpyrazolo[3,4-d][1,3]oxazin-4-one Chemical group [O-][N+](=O)C1=CC([N+](=O)[O-])=CC(C=2OC(=O)C=3C=NN(C=3N=2)C=2C=CC=CC=2)=C1 XIBUCANHNLRVFI-UHFFFAOYSA-N 0.000 claims description 4
- 229940045799 anthracyclines and related substance Drugs 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- 229940126062 Compound A Drugs 0.000 claims description 3
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims description 3
- 229940034982 antineoplastic agent Drugs 0.000 claims description 3
- 229960004679 doxorubicin Drugs 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims description 3
- 229940009456 adriamycin Drugs 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 230000036436 anti-hiv Effects 0.000 claims description 2
- 229940088710 antibiotic agent Drugs 0.000 claims description 2
- 239000003435 antirheumatic agent Substances 0.000 claims description 2
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 239000003018 immunosuppressive agent Substances 0.000 claims description 2
- 230000005764 inhibitory process Effects 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 239000002417 nutraceutical Substances 0.000 claims description 2
- 235000021436 nutraceutical agent Nutrition 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 239000006186 oral dosage form Substances 0.000 claims description 2
- 239000006201 parenteral dosage form Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000008174 sterile solution Substances 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 238000013268 sustained release Methods 0.000 claims description 2
- 239000012730 sustained-release form Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000006208 topical dosage form Substances 0.000 claims description 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims description 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims description 2
- 241000700605 Viruses Species 0.000 claims 1
- 208000035269 cancer or benign tumor Diseases 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 abstract description 12
- -1 3, 5-dinitrophenyl Chemical group 0.000 abstract description 10
- 238000011160 research Methods 0.000 abstract description 9
- 238000011282 treatment Methods 0.000 abstract description 9
- 229940041181 antineoplastic drug Drugs 0.000 abstract description 7
- 230000002441 reversible effect Effects 0.000 abstract description 7
- 230000035945 sensitivity Effects 0.000 abstract description 7
- 238000009098 adjuvant therapy Methods 0.000 abstract description 2
- 238000002512 chemotherapy Methods 0.000 abstract description 2
- 231100000252 nontoxic Toxicity 0.000 abstract description 2
- 230000003000 nontoxic effect Effects 0.000 abstract description 2
- 238000011260 co-administration Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 11
- 230000036457 multidrug resistance Effects 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 3
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 3
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 3
- 230000002018 overexpression Effects 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 3
- 102000005416 ATP-Binding Cassette Transporters Human genes 0.000 description 2
- 108010006533 ATP-Binding Cassette Transporters Proteins 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 229940044683 chemotherapy drug Drugs 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000011287 therapeutic dose Methods 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to the technical field of medicines, and relates to application of 3, 5-dinitrophenyl-pyrazolo [3,4-d ] [1,3] oxazine as a tumor drug resistance reversal agent. The research of the invention shows that 1-phenyl-6- (3, 5-dinitrophenyl) -pyrazolo [3,4-d ] [1,3] oxazine-4 (1H) -ketone can remarkably improve the sensitivity of tumor cells to anti-tumor drugs and reverse the drug resistance of the tumor cells, and the treatment dosage is safe and nontoxic, and the invention has the potential to become a novel tumor drug resistance reversal agent drug. Based on the research result, the compound can be used for adjuvant therapy of a chemotherapy scheme and co-administration with other anti-tumor drugs, and has good clinical medication significance.
Description
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to an application of a 3, 5-dinitrophenyl-pyrazolo [3,4-d ] [1,3] oxazine compound, namely 1-phenyl-6- (3, 5-dinitrophenyl) -pyrazolo [3,4-d ] [1,3] oxazine-4 (1H) -ketone as a tumor drug resistance reversal agent, and an application of a pharmaceutical composition comprising 1-phenyl-6- (3, 5-dinitrophenyl) -pyrazolo [3,4-d ] [1,3] oxazine-4 (1H) -ketone in preparation of an antitumor agent.
Background
The information in this background section is only for enhancement of understanding of the general background of the invention and is not necessarily to be construed as an admission or any form of suggestion that this information forms the prior art that is already known to a person of ordinary skill in the art.
Multidrug resistance (MDR) of tumors has been a worldwide problem that plagues cancer treatment, and MDR refers to the long-term exposure of tumor cells to a certain chemotherapeutic drug, which results in drug resistance, and may also result in cross-resistance of other multiple chemotherapeutic drugs with different functions, which is one of the main causes of chemotherapy failure. The mechanism of MDR in tumors is complex, with overexpression of ABC transporters being the major cause of MDR. Therefore, efforts to find and develop MDR reversal agents to restore sensitivity of MDR cells to traditional anticancer drugs are considered as the main strategy to overcome MDR.
ABCG2 is one of the key proteins responsible for MDR and belongs to the second-position member of the G subfamily of the ABC transporter superfamily. The ABCG2 transporter can pump antitumor drugs such as mitoxantrone, gefitinib, adriamycin and imatinib from the inside to the outside of cells, thereby reducing the antitumor effect of the drugs. The research finds that the ABCG2 has direct clinical relevance to the staging, metastasis and prognosis of the breast cancer, and has clear connection with the survival rate and treatment response of patients with diffuse large B-cell lymphoma, acute myelogenous leukemia and non-small cell lung cancer. Therefore, blocking the efflux of ABCG2 is of great significance in the treatment of drug resistant tumors.
Disclosure of Invention
Based on the research background, the invention discovers that the compound 1-phenyl-6- (3, 5-dinitrophenyl) -pyrazolo [3,4-d ] [1,3] oxazine-4 (1H) -ketone can target ABCG2, has an inhibiting effect, improves the sensitivity of tumor cells to drugs, and is expected to be applied to the treatment of drug-resistant tumors.
In order to achieve the technical purpose, the invention adopts the following technical scheme:
in a first aspect of the invention, there is provided the use of 3, 5-dinitrophenyl-pyrazolo [3,4-d ] [1,3] oxazines as reversal agents of tumour resistance.
Wherein the 3, 5-dinitrophenyl-pyrazolo [3,4-d ] [1,3] oxazine is 1-phenyl-6- (3, 5-dinitrophenyl) -pyrazolo [3,4-d ] [1,3] oxazine-4 (1H) -ketone, and the structural formula is as follows:
the research of the invention shows that the compound shown in the formula I can reverse the drug resistance of tumor cells and improve the sensitivity of the tumor cells to antitumor drugs. Preferably, the compound can inhibit the activity of ABCG2 in tumor cells, reduce the pumping out of anticancer drugs and improve the sensitivity of the antitumor drugs related to the ABCG2 drug resistance route. In addition, cytotoxicity experiments also confirmed that there was no significant toxicity at therapeutic doses. The results show that the 1-phenyl-6- (3, 5-dinitrophenyl) -pyrazolo [3,4-d ] [1,3] oxazine-4 (1H) -ketone can reverse the drug resistance degree of tumor cells, and has adjuvant therapy effect on tumors and drug-resistant tumors.
In a second aspect, the invention provides the application of 3, 5-dinitrophenyl-pyrazolo [3,4-d ] [1,3] oxazine in preparing a medicament with an inhibitory effect on drug-resistant protein (ABCG 2).
In a third aspect of the present invention, there is provided a pharmaceutical composition comprising: compound a and a pharmaceutically acceptable carrier;
wherein the compound A is 3, 5-dinitrophenyl-pyrazolo [3,4-d ] [1,3] oxazine.
In a fourth aspect of the present invention, there is provided an application of any one of the above pharmaceutical compositions in the preparation of an anti-tumor agent.
The invention has the beneficial effects that:
(1) the research of the invention proves that the therapeutic dose of the compound is far lower than the minimum toxic dose through in vitro cell experiments, and the use is safe.
(2) The research result of the invention proves that 1-phenyl-6- (3, 5-dinitrophenyl) -pyrazolo [3,4-d ] [1,3] oxazine-4 (1H) -ketone (a compound shown in a formula I) inhibits the expression of ABCG2 in tumor cells, and realizes the reversal effect of drug-resistant tumor cells. The research result of the invention provides the effect of the compound in resisting tumors, particularly drug-resistant tumors for the first time.
(3) Tumors related to ABCG2 drug resistance have been reported to include non-small cell lung cancer, diffuse large B-cell lymphoma, acute myelogenous leukemia and the like. Based on the research result of the invention, the combined application treatment method of the compound and the disease treatment medicine can be correspondingly developed, and the invention has good guiding significance for clinical medication.
Detailed Description
It is to be understood that the following detailed description is exemplary and is intended to provide further explanation of the invention as claimed. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
It is noted that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of exemplary embodiments according to the invention. As used herein, the singular forms "a", "an" and "the" are intended to include the plural forms as well, and it should be understood that when the terms "comprises" and/or "comprising" are used in this specification, they specify the presence of stated features, steps, operations, devices, components, and/or combinations thereof, unless the context clearly indicates otherwise.
As introduced in the background art, aiming at the defects in the prior art, the invention provides the application of 1-phenyl-6- (3, 5-dinitrophenyl) -pyrazolo [3,4-d ] [1,3] oxazine-4 (1H) -ketone as a tumor drug resistance reversal agent in order to solve the technical problems.
In a first aspect of the invention, the invention provides a compound selected from compounds shown in formula I, or pharmaceutically acceptable salts, solvates and hydrates thereof, and the compound is used as a tumor drug resistance reversal agent.
In some embodiments, the tumor resistance-reversing agent is a transport pump inhibitor.
In some embodiments, the transport pump inhibitor has an inhibitory effect on drug resistance protein (ABCG 2).
In some embodiments, the tumor resistance reversal agent is an inhibitor of drug resistance protein (ABCG2) transport.
In some specific embodiments, the tumor-resistant drug is mitoxantrone or doxorubicin.
In a second aspect of the present invention, a pharmaceutical composition is provided, where the pharmaceutical composition includes one or more of the compound described in the first aspect, a pharmaceutically acceptable salt, a solvate, and a hydrate of the compound, and a pharmaceutically acceptable carrier.
In some embodiments, the pharmaceutical composition further comprises a drug for treating or assisting in treating tumors.
In some embodiments, the drugs for treating or adjunctively treating tumors include, but are not limited to, camptothecin analogs, tyrosine kinase inhibitors, anthracyclines, anti-HIV viral drugs, anti-rheumatic drugs, immunosuppressive agents, and antibiotics.
In some embodiments, the drug for treating a tumor is an ABCG2 drug resistance-related drug.
In some embodiments, the anthracycline is mitoxantrone or doxorubicin.
In some embodiments, the pharmaceutical composition includes, but is not limited to, oral dosage forms, parenteral dosage forms, topical dosage forms, and rectal dosage forms.
In some embodiments, the pharmaceutical composition may be tablets, capsules, pills, powders, sustained release formulations, solutions and suspensions for oral administration, sterile solutions, suspensions or emulsions for parenteral injection, ointments or creams for topical use, or suppositories for rectal administration.
In a third aspect of the present invention, there is provided the use of a compound according to the first aspect or a pharmaceutical composition according to the second aspect in the manufacture of an anti-neoplastic agent.
In some embodiments, the anti-tumor agent comprises drugs, nutraceuticals, and model tool drugs for treating tumors.
In a fourth aspect of the invention, there is provided a method of treatment of a tumour which comprises treatment with a compound according to the first aspect or a pharmaceutical composition according to the second aspect.
In some embodiments, the tumor is a drug-resistant tumor disease, further including, but not limited to, drug-resistant breast cancer, drug-resistant non-small cell lung cancer, drug-resistant diffuse large B-cell lymphoma, drug-resistant acute myelogenous leukemia.
The present invention is described in further detail below with reference to specific examples, which are intended to be illustrative of the invention and not limiting.
EXAMPLE 1 test for reversing drug resistance of Compounds to tumor cells
1. And (3) drug-resistant cell culture: S1-MI-80 cells are MX-induced ABCG2 overexpression resistant sublines derived from human colon cancer cell line S123. S1-MI-80 was cultured in DMEM medium. All cell lines were maintained at 37 ℃ with 5% CO2In a moist incubator.
2. Cytotoxicity test: drug sensitivity in vitro cell models was determined using MTT colorimetric cell proliferation assays. Single cell suspensions were prepared and seeded at 160. mu.L per well in 96-well plates, and CO was placed2Culturing in incubator for 24 hr, adding a series of concentrations (0, 1, 2, 4, 8, 18, 32 μmol/L) of 1-phenyl-6- (3, 5-dinitrophenyl) -pyrazolo [3,4-d][1,3]Oxazin-4 (1H) -ones. mu.L of 0.5% MTT was added to each well and incubated for an additional 4 hours. The supernatant was then removed and 150 μ L DMSO was added to each well to dissolve the MTT crystals. Absorbance was measured at 540nm using a microplate reader, and the essentially non-toxic dose was determined.
3. Drug resistance reversal activity test: single cell suspensions were prepared and seeded at 160. mu.L per well in 96-well plates, 20 addedMu mol/L1-phenyl-6- (3, 5-dinitrophenyl) -pyrazolo [3,4-d][1,3]Oxazin-4 (1H) -one, ko143 (2.5. mu. mol/L) was used as a positive control. After 1h incubation, a series of different concentrations (100, 200, 400, 800, 1600, 3200nM) of mitoxantrone were added. After 68 hours of incubation, 20. mu.L of 0.5% MTT was added and incubated for an additional 4 hours. The supernatant was removed and 150 μ L DMSO was added to each well to dissolve the MTT crystals. Absorbance was measured at 540nm with a microplate reader, and IC was calculated by Bliss method50Value (IC)50The value is the concentration of the compound corresponding to 50% inhibition of the viability of the cells) and the reversal factor of drug resistance RF (mitoxantrone on sensitive tumor cells IC) is calculated50value/Compound in combination with mitoxantrone on drug resistant cell IC50)。
Drug resistance reversal activity of the compounds of Table 1
The results are shown in table 1, with the known ABCG2 inhibitor Ko143 as a positive control group. The sensitivity of the drug-resistant cell strain treated by 1-phenyl-6- (3, 5-dinitrophenyl) -pyrazolo [3,4-d ] [1,3] oxazine-4 (1H) -ketone to mitoxantrone is remarkably improved, the drug resistance reversal fold RF value is 6.10, the reversal activity is close to positive control Ko143, and the drug resistance of the ABCG2 over-expression drug-resistant cell S1-MI-80 can be effectively reversed.
It should be noted that the above-mentioned embodiments are only preferred embodiments of the present invention, and the present invention is not limited thereto, and although the present invention has been described in detail with reference to the foregoing embodiments, it will be apparent to those skilled in the art that modifications and equivalents can be made in the technical solutions described in the foregoing embodiments, or equivalents thereof. Any modification, equivalent replacement, or improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention. Although the present invention has been described with reference to the specific embodiments, it should be understood by those skilled in the art that various changes and modifications may be made without departing from the spirit and scope of the invention.
Claims (10)
- The application of 3, 5-dinitrophenyl-pyrazolo [3,4-d ] [1,3] oxazine as tumor drug resistance reversal agent is provided.
- 2. The use according to claim 1, wherein the 3, 5-dinitrophenyl-pyrazolo [3,4-d ] [1,3] oxazine is 1-phenyl-6- (3, 5-dinitrophenyl) -pyrazolo [3,4-d ] [1,3] oxazin-4 (1H) -one of the formula:
- 3. the use of claim 1, wherein the tumor resistance-reversing agent is a transport pump inhibitor;preferably, the tumor drug resistance reversal agent is a drug-resistant protein transport inhibitor;more preferably, the tumor-resistant drug is mitoxantrone or doxorubicin.
- Application of 3, 5-dinitrophenyl-pyrazolo [3,4-d ] [1,3] oxazine in preparation of drugs with inhibition effect on drug-resistant protein (ABCG 2).
- 5. The use according to claim 4, wherein the 3, 5-dinitrophenyl-pyrazolo [3,4-d ] [1,3] oxazine is 1-phenyl-6- (3, 5-dinitrophenyl) -pyrazolo [3,4-d ] [1,3] oxazin-4 (1H) -one of the formula:
- 6. a pharmaceutical composition, comprising: compound a and a pharmaceutically acceptable carrier;wherein the compound A is 3, 5-dinitrophenyl-pyrazolo [3,4-d ] [1,3] oxazine.
- 7. The pharmaceutical composition according to claim 6, wherein compound A is 1-phenyl-6- (3, 5-dinitrophenyl) -pyrazolo [3,4-d ] [1,3] oxazin-4 (1H) -one.
- 8. The pharmaceutical composition of claim 6, further comprising a drug for treating or adjunctively treating a tumor;preferably, the drugs for treating or assisting in treating tumors include, but are not limited to, camptothecin analogs, tyrosine kinase inhibitors, anthracyclines, anti-HIV virus drugs, antirheumatic drugs, immunosuppressants and antibiotics;or the medicine for treating the tumor is an ABCG2 medicine-resistance related medicine; or the anthracycline medicine is mitoxantrone or adriamycin;or, the pharmaceutical composition includes, but is not limited to, oral dosage forms, parenteral dosage forms, topical dosage forms, and rectal dosage forms; preferably, the pharmaceutical composition may be tablets, capsules, pills, powders, sustained release formulations, solutions and suspensions for oral administration, sterile solutions, suspensions or emulsions for parenteral injection, ointments or creams for external use, or suppositories for rectal administration.
- 9. Use of a pharmaceutical composition according to any one of claims 6 to 8 for the preparation of an anti-tumor agent.
- 10. The use of a compound or pharmaceutical composition of claim 9 in the preparation of an anti-neoplastic agent, wherein the anti-neoplastic agent comprises a drug for treating a neoplasm, a nutraceutical, and a model tool drug.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011350126.3A CN112402425B (en) | 2020-11-26 | 2020-11-26 | Application of 3, 5-dinitrophenyl-pyrazolo [3,4-d ] [1,3] oxazine as tumor drug resistance reversal agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011350126.3A CN112402425B (en) | 2020-11-26 | 2020-11-26 | Application of 3, 5-dinitrophenyl-pyrazolo [3,4-d ] [1,3] oxazine as tumor drug resistance reversal agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112402425A true CN112402425A (en) | 2021-02-26 |
| CN112402425B CN112402425B (en) | 2021-12-03 |
Family
ID=74843242
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011350126.3A Active CN112402425B (en) | 2020-11-26 | 2020-11-26 | Application of 3, 5-dinitrophenyl-pyrazolo [3,4-d ] [1,3] oxazine as tumor drug resistance reversal agent |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112402425B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111388477A (en) * | 2020-04-24 | 2020-07-10 | 山东师范大学 | Application of 2-phenylpyrazole [1,5-a ] pyrimidine compound as tumor drug resistance reversal agent |
| CN111467341A (en) * | 2020-04-24 | 2020-07-31 | 山东师范大学 | Application of 3, 4-dimethoxyphenyl-benzo [ d ] oxazole as tumor drug resistance reversal agent |
-
2020
- 2020-11-26 CN CN202011350126.3A patent/CN112402425B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111388477A (en) * | 2020-04-24 | 2020-07-10 | 山东师范大学 | Application of 2-phenylpyrazole [1,5-a ] pyrimidine compound as tumor drug resistance reversal agent |
| CN111467341A (en) * | 2020-04-24 | 2020-07-31 | 山东师范大学 | Application of 3, 4-dimethoxyphenyl-benzo [ d ] oxazole as tumor drug resistance reversal agent |
Non-Patent Citations (3)
| Title |
|---|
| CHE,JUN等: "Traceless solid-phase Synthesis of Heteroannulated 1,3-Oxazin-6-ones", 《JOURNAL OF COMBINATORIAL CHEMISTRY》 * |
| 刘蒙等: "多种结肠癌5-氟尿嘧啶耐药细胞株的建立及耐药机制初步研究", 《中国普通外科杂志》 * |
| 江明华等主编: "《生化药理学》", 31 August 2004 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112402425B (en) | 2021-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11446309B2 (en) | Combination therapy for cancer using bromodomain and extra-terminal (BET) protein inhibitors | |
| DK2799070T3 (en) | EFFECTIVE AMPLIFIER FOR ANTITUMUM AGENTS | |
| NZ506187A (en) | Use of epothilones for the treatment of cancer | |
| JP2009263371A (en) | Anti-cancer combination | |
| WO2008133866A1 (en) | Polymorph of dihydropyrazolopyrimidinone derivative as weel kinase.inhibitor | |
| EP2979700B1 (en) | Antitumor agent including low dose irinotecan hydrochloride hydrate | |
| CN110478487B (en) | Application of macrolide compound in reversing tumor multidrug resistance and enhancing anti-tumor curative effect | |
| WO2015115310A1 (en) | Cancer stem cell proliferation inhibitor and intracellular active oxygen accumulation inducer | |
| JP2013511487A (en) | A therapeutic combination comprising a Cdc7 inhibitor and an antineoplastic agent | |
| WO2010101734A1 (en) | Combination cancer therapy with an akt inhibitor and other anticancer agents | |
| WO2019176984A1 (en) | Antitumor agent, antitumor effect potentiator and antitumor kit | |
| CN111388477B (en) | Application of 2-phenylpyrazole [1,5-a ] pyrimidine compound as tumor drug resistance reversal agent | |
| CN112402425B (en) | Application of 3, 5-dinitrophenyl-pyrazolo [3,4-d ] [1,3] oxazine as tumor drug resistance reversal agent | |
| CN111467341B (en) | Application of 3, 4-dimethoxyphenyl-benzo [ d ] oxazole as tumor drug resistance reversal agent | |
| WO2020254299A1 (en) | Combination of a mcl-1 inhibitor and a standard of care treatment for breast cancer, uses and pharmaceutical compositions thereof | |
| CN111821303B (en) | Application of vortioxetine and salts thereof in preparation of antitumor drugs | |
| CN111388463B (en) | Application of epimedin C or composition in preparation of preparation for treating lung cancer | |
| CN108992463B (en) | Composition and medicinal preparation for treating lung cancer | |
| US20100087399A1 (en) | Use of 9-oxoacridine-10-acetic acid, salts and esters thereof in combination therapy of ovarian cancer | |
| CN114173779A (en) | Therapeutic agents for cancer resistant to anti-CCR 4 antibodies | |
| WO2022198777A1 (en) | Application of triazole compound in preparation of antitumor drugs | |
| CN111297870B (en) | Application of nitrobenzoic acid compounds in preparation of drugs for treating tumors | |
| CN110693903B (en) | Medicine for treating acute monocytic leukemia and application of arsenic trioxide and dihydroartemisinin | |
| US11179349B2 (en) | Use of tumor gene methylation regulator and anti-tumor drugs | |
| CA3198190A1 (en) | Use of sodium trans-[tetrachloridobis(1h-indazole)ruthenate(iii)] for treating cancers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20230411 Address after: 2081, building a, 88 Jianghai West Road, Liangxi District, Wuxi City, Jiangsu Province, 214000 Patentee after: Wuxi Xiangyuan Information Technology Co.,Ltd. Address before: 250014 No. 88, Wenhua East Road, Lixia District, Shandong, Ji'nan Patentee before: SHANDONG NORMAL University |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20240430 Address after: 201400 Building 1, No.1 Haikun Road, Fengxian District, Shanghai Patentee after: Shanghai Xianglihe Pharmaceutical Co.,Ltd. Country or region after: China Address before: 2081, building a, 88 Jianghai West Road, Liangxi District, Wuxi City, Jiangsu Province, 214000 Patentee before: Wuxi Xiangyuan Information Technology Co.,Ltd. Country or region before: China |